

6/10 VRPAC Discussion Questions:

1. Provided there is sufficient evidence of effectiveness to support benefit of a COVID-19 preventive vaccine for pediatric age groups (e.g., 6 to <12 years, 2 to <6 years, and 6 months to <2 years), please discuss the safety data, including database size and duration of follow-up, that would support:
  - a. Emergency Use Authorization
  - b. Licensure
2. Provided there is sufficient evidence of effectiveness to support benefit of a COVID-19 preventive vaccine for adolescents 12 to <18 years of age, please discuss the safety data, including database size and duration of follow-up, that would support licensure.
3. Please discuss studies following licensure and/or issuance of an EUA to further evaluate safety and effectiveness of COVID-19 vaccines in different pediatric age groups.